S&P 500   4,577.10 (+1.42%)
DOW   34,639.79 (+1.82%)
QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
S&P 500   4,577.10 (+1.42%)
DOW   34,639.79 (+1.82%)
QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
S&P 500   4,577.10 (+1.42%)
DOW   34,639.79 (+1.82%)
QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
S&P 500   4,577.10 (+1.42%)
DOW   34,639.79 (+1.82%)
QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
NASDAQ:VERU

Veru Stock Forecast, Price & News

$6.95
+0.04 (+0.58%)
(As of 12/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.55
$7.16
50-Day Range
$6.91
$9.73
52-Week Range
$3.13
$24.57
Volume
1.76 million shs
Average Volume
1.87 million shs
Market Capitalization
$554.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.5
30 days | 90 days | 365 days | Advanced Chart
Receive VERU News and Ratings via Email

Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter.


Veru logo

About Veru

Veru, Inc. is an oncology biopharmaceutical company engaged in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer; and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT. The firm's breast cancer drug candidates include: Enobosarm, an oral, new chemical entity, selective androgen receptor agonist that targets the androgen receptor in AR+/ER+/HER2-hormone sensitive metastatic breast cancer without unwanted virilizing side effects; and VERU 111 for triple negative metastatic breast cancer that has become resistant to taxane IV chemotherapy. It is also advancing the new drug formulation TADFYN, tadalafil and finasterid

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Personal Products
Sector
Medical
Current Symbol
NASDAQ:VERU
CUSIP
31446210
Employees
339
Year Founded
N/A

Sales & Book Value

Annual Sales
$42.59 million
Book Value
$0.43 per share

Profitability

Net Income
$-18.97 million
Pretax Margin
-7.02%

Debt

Price-To-Earnings

Miscellaneous

Free Float
60,210,000
Market Cap
$554.99 million
Optionable
Optionable

Company Calendar

Last Earnings
8/12/2021
Today
12/02/2021
Next Earnings (Confirmed)
12/02/2021
Fiscal Year End
9/30/2022

MarketRank

Overall MarketRank

2.12 out of 5 stars

Medical Sector

481st out of 1,391 stocks

Pharmaceutical Preparations Industry

219th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Veru (NASDAQ:VERU) Frequently Asked Questions

Is Veru a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Veru stock.
View analyst ratings for Veru
or view top-rated stocks.

How has Veru's stock been impacted by COVID-19 (Coronavirus)?

Veru's stock was trading at $3.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VERU shares have increased by 117.2% and is now trading at $6.95.
View which stocks have been most impacted by COVID-19
.

When is Veru's next earnings date?

Veru is scheduled to release its next quarterly earnings announcement on Thursday, December 2nd 2021.
View our earnings forecast for Veru
.

How were Veru's earnings last quarter?

Veru Inc. (NASDAQ:VERU) released its quarterly earnings results on Thursday, August, 12th. The company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.06) by $0.03. The business had revenue of $17.66 million for the quarter, compared to analysts' expectations of $13.98 million. Veru had a negative net margin of 0.25% and a negative trailing twelve-month return on equity of 7.62%.
View Veru's earnings history
.

What price target have analysts set for VERU?

5 Wall Street analysts have issued 1-year price targets for Veru's shares. Their forecasts range from $15.00 to $26.00. On average, they expect Veru's stock price to reach $19.60 in the next twelve months. This suggests a possible upside of 182.0% from the stock's current price.
View analysts' price targets for Veru
or view top-rated stocks among Wall Street analysts.

Who are Veru's key executives?

Veru's management team includes the following people:
  • Mitchell Shuster Steiner, Chairman, President & Chief Executive Officer
  • Michele Greco, Chief Financial & Administrative Officer
  • Robert H. Getzenberg, Executive Vice President-Medical Affairs
  • Domingo Rodriguez, Executive Vice President-Clinical Operations
  • K. Gary Barnette, Chief Scientific Officer

What other stocks do shareholders of Veru own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include (KDMN), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Matinas BioPharma (MTNB), OrganiGram (OGI), Vaxart (VXRT), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

What is Veru's stock symbol?

Veru trades on the NASDAQ under the ticker symbol "VERU."

Who are Veru's major shareholders?

Veru's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.31%), Geode Capital Management LLC (1.34%), Millennium Management LLC (0.68%), Morgan Stanley (0.43%), Goldman Sachs Group Inc. (0.40%) and Jane Street Group LLC (0.00%). Company insiders that own Veru stock include Harry Fisch, Jesus Socorro, K Gary Barnette, Lucy Lu, Michele Greco and Mitchell Shuster Steiner.
View institutional ownership trends for Veru
.

Which institutional investors are selling Veru stock?

VERU stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Renaissance Technologies LLC, Citadel Advisors LLC, Jane Street Group LLC, Morgan Stanley, Oppenheimer & Co. Inc., UBS Group AG, and Voloridge Investment Management LLC. Company insiders that have sold Veru company stock in the last year include Harry Fisch, K Gary Barnette, and Mitchell Shuster Steiner.
View insider buying and selling activity for Veru
or view top insider-selling stocks.

Which institutional investors are buying Veru stock?

VERU stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Goldman Sachs Group Inc., Marshall Wace LLP, BlackRock Inc., GSA Capital Partners LLP, Two Sigma Advisers LP, Healthcare of Ontario Pension Plan Trust Fund, and Level Four Advisory Services LLC. Company insiders that have bought Veru stock in the last two years include Harry Fisch, Jesus Socorro, Lucy Lu, and Michele Greco.
View insider buying and selling activity for Veru
or or view top insider-buying stocks.

How do I buy shares of Veru?

Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veru's stock price today?

One share of VERU stock can currently be purchased for approximately $6.95.

How much money does Veru make?

Veru has a market capitalization of $554.99 million and generates $42.59 million in revenue each year. The company earns $-18.97 million in net income (profit) each year or ($0.01) on an earnings per share basis.

How many employees does Veru have?

Veru employs 339 workers across the globe.

What is Veru's official website?

The official website for Veru is www.veruhealthcare.com.

Where are Veru's headquarters?

How can I contact Veru?

Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The company can be reached via phone at (305) 509-6897, via email at [email protected], or via fax at 312-595-9122.


This page was last updated on 12/2/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.